Last reviewed · How we verify
Triptorelin embonate 22.5 mg — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Triptorelin embonate 22.5 mg (Triptorelin embonate 22.5 mg) — Ipsen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Triptorelin embonate 22.5 mg TARGET | Triptorelin embonate 22.5 mg | Ipsen | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Triptorelin embonate 22.5 mg CI watch — RSS
- Triptorelin embonate 22.5 mg CI watch — Atom
- Triptorelin embonate 22.5 mg CI watch — JSON
- Triptorelin embonate 22.5 mg alone — RSS
Cite this brief
Drug Landscape (2026). Triptorelin embonate 22.5 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/triptorelin-embonate-22-5-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab